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Renal cell carcinoma (RCC) has some unique characteristics that are not observed in 
other cancers, such as a relatively high frequency of late recurrence (LR) after radical 
surgery.1 In a study by Kobayashi et al.,2 the Kaplan–Meier curves of overall survival 
(OS), disease-specific survival (DSS), and recurrence-free survival went linearly down 
for 15 years after radical surgery and did not plateau. Although some 
clinicopathological features of LR in RCC have been revealed in recent studies, their 
cause remains unclear. 
LR is usually defined as recurrence more than 5 years after radical surgery. To 
characterize the clinical outcomes of all patients treated with radical surgery, it is 
reasonable to compare patients with LR to not only patients with early recurrence (ER; 
within 5 years after radical surgery) but also those without recurrence. A large study by 
Kroger et al.3 including 1,210 patients reported that compared with patients with ER, 
patients with LR were younger and showed fewer sarcomatoid features, more clear cell 
histology, and lower Fuhrman grade. The latest study on Japanese patients by Fujii et 
al.4 revealed the following parameters to be independent predictive factors of ER: 
positive symptoms at diagnosis, ≥pT2, positive lymphovascular invasion, and 
histological grade 3; these results were similar to those of Kobayashi et al.2 However, 
both Kroger et al.3 and Fujii et al.4 did not include patients without recurrence after 5 
years of radical surgery. It might be difficult to compare patients with LR to those 
without recurrence because the latter have the potential to relapse any time. Kobayashi 
et al.2 reported that vascular invasion alone was the predictor of LR in multivariate 
analysis of patients who remained free of recurrence at 5 years after radical surgery. 
This result might be clinically significant with regard to follow-up schedule of such 
patients. Kaplan–Meier curves of OS and DSS in patients with LR further went linearly 
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down by at least 5 years after recurrence. Moreover, non-recurrence may contribute to 
the extension of survival. To appropriately treat recurrence, it should be detected as 
early as possible, and clinicians can shorten the follow-up interval of patients with 
vascular invasion.  
Regardless of the study backgrounds, a common result of comparison between ER and 
LR was that patients with LR had a much better survival after recurrence. Bozkurt et al.5 
reported that patients with LR had a better response to sunitinib than did those with ER. 
Although slow growth may be a characteristic of LR, it is still unclear whether there are 
differences in responses to treatments such as molecular targeted therapies, cytokine 
therapies, and metastasectomy between ER and LR. Further larger studies are warranted 
to clarify the difference of response to treatments between ER and LR and the best 
follow-up schedule to appropriately identify recurrence in patients with RCC during a 
long follow-up time. 
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